ResMed CFO Executes Quiet 1,000‑Share Sale Amid Steady Q2 Earnings, Sparking Insider‑Trading Speculation.
ResMed CFO Brett Sandercock sells 1,000 shares at $257.03 under a Rule 10b‑5‑1 plan, sparking modest market reaction and prompting investors to monitor insider‑trading patterns amid solid earnings and steady fundamentals.
3 minutes to read